- 질문내용 -
I'm on business s gra 100 pills The Food and Drug Administration is investigating a reported case of the brain infection progressive multifocal leukoencephalopathy in a patient taking the Novartis MS drug Gilenya in Europe. The regulator announced the investigation Thursday and said in a statement that this is the first case of PML reported in a Gilenya patient who has not taken Biogen Idec's Tysabri, which the regulator notes has been associated with a higher risk of PML.
|
|
